Background: Major Depressive Disorder (MDD) is a psychiatric disorder with a highly recurrent character, making prevention of relapse an important clinical goal. Preventive Cognitive Therapy (PCT) has been proven effective in preventing relapse, though not for every patient. A better understanding of relapse vulnerability and working mechanisms of preventive treatment may inform effective personalized intervention strategies. Neurocognitive models of MDD suggest that abnormalities in prefrontal control over limbic emotion-processing areas during emotional processing and regulation are important in understanding relapse vulnerability. Whether changes in these neurocognitive abnormalities are induced by PCT and thus play an important role in mediating the risk for recurrent depression, is currently unclear. In the Neurocognitive Working Mechanisms of the Prevention of Relapse In Depression (NEWPRIDE) study, we aim to 1) study neurocognitive factors underpinning the vulnerability for relapse, 2) understand the neurocognitive working mechanisms of PCT, 3) predict longitudinal treatment effects based on pre-treatment neurocognitive characteristics, and 4) validate the pupil dilation response as a marker for prefrontal activity, reflecting emotion regulation capacity and therapy success.
Methods: In this randomized controlled trial, 75 remitted recurrent MDD (rrMDD) patients will be included. Detailed clinical and cognitive measurements, fMRI scanning and pupillometry will be performed at baseline and three-month follow-up. In the interval, 50 rrMDD patients will be randomized to eight sessions of PCT and 25 rrMDD patients to a waiting list. At baseline, 25 healthy control participants will be additionally included to objectify cross-sectional residual neurocognitive abnormalities in rrMDD. After 18 months, clinical assessments of relapse status are performed to investigate which therapy induced changes predict relapse in the 50 patients allocated to PCT.
Discussion: The present trial is the first to study the neurocognitive vulnerability factors underlying relapse and mediating relapse prevention, their value for predicting PCT success and whether pupil dilation acts as a valuable marker in this regard. Ultimately, a deeper understanding of relapse prevention could contribute to the development of better targeted preventive interventions.
Trial registration: Trial registration: Netherlands Trial Register, August 18, 2015, trial number NL5219.
Keywords: Functional neuroimaging; Major depressive disorder; Neurocognitive mechanisms; Prevention; Randomized controlled trial; Recurrence; Remission; Therapy prediction.
Conflict of interest statement
The authors declare that they have no competing interests.
Enduring effects of Preventive Cognitive Therapy in adults remitted from recurrent depression: A 10 year follow-up of a randomized controlled trial.J Affect Disord. 2015 Oct 1;185:188-94. doi: 10.1016/j.jad.2015.06.048. Epub 2015 Jul 11. J Affect Disord. 2015. PMID: 26188380 Clinical Trial.
Preventive Cognitive Therapy versus Treatment as Usual in preventing recurrence of depression: protocol of a multi-centered randomized controlled trial.BMC Psychiatry. 2015 Jul 1;15:139. doi: 10.1186/s12888-015-0508-8. BMC Psychiatry. 2015. PMID: 26129694 Free PMC article. Clinical Trial.
Vulnerability for new episodes in recurrent major depressive disorder: protocol for the longitudinal DELTA-neuroimaging cohort study.BMJ Open. 2016 Mar 1;6(3):e009510. doi: 10.1136/bmjopen-2015-009510. BMJ Open. 2016. PMID: 26932139 Free PMC article.
Interventions for preventing relapse and recurrence of a depressive disorder in children and adolescents.Cochrane Database Syst Rev. 2012 Nov 14;11:CD007504. doi: 10.1002/14651858.CD007504.pub2. Cochrane Database Syst Rev. 2012. PMID: 23152246 Review.
Characterizing neurocognitive impairment in young people with major depression: state, trait, or scar?Brain Behav. 2016 Jul 21;6(10):e00527. doi: 10.1002/brb3.527. eCollection 2016 Oct. Brain Behav. 2016. PMID: 27781141 Free PMC article. Review.